Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 607.57K | 253.57K | 223.21K | 1.16M | 2.18M |
Gross Profit | 222.81K | -220.98K | -209.16K | 309.60K | 1.48M |
EBITDA | -7.88M | -1.43M | -2.11M | -1.01M | -341.17K |
Net Income | -7.95M | -3.77M | -6.18M | -4.25M | -3.03M |
Balance Sheet | |||||
Total Assets | 5.76M | 7.78M | 1.30M | 1.39M | 2.61M |
Cash, Cash Equivalents and Short-Term Investments | 3.39M | 2.14M | 264.87K | 115.40K | 191.70K |
Total Debt | 155.89K | 172.67K | 22.42M | 18.80M | 19.14M |
Total Liabilities | 1.87M | 2.99M | 25.45M | 19.55M | 20.68M |
Stockholders Equity | 4.04M | 4.87M | -23.58M | -17.58M | -17.50M |
Cash Flow | |||||
Free Cash Flow | -5.83M | -4.66M | -1.07M | -684.50K | -238.28K |
Operating Cash Flow | -5.65M | -4.54M | -1.01M | -649.11K | -167.30K |
Investing Cash Flow | -1.89M | -115.89K | -60.13K | -35.39K | -70.98K |
Financing Cash Flow | 7.05M | 6.47M | 1.22M | 611.23K | 277.36K |
On July 15, 2025, 60 Degrees Pharmaceuticals, Inc. announced a Securities Purchase Agreement with institutional investors for a follow-on offering, which included shares of common stock and various warrants. The offering, which closed on July 16, 2025, generated approximately $5 million in gross proceeds, intended for general corporate purposes and working capital. The offering was made under the company’s registration statement declared effective by the SEC. This move is expected to impact the company’s financial operations and market positioning by providing additional capital for its ongoing projects.
The most recent analyst rating on (SXTP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.